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BACKGROUND: Myeloid cells are central to atherosclerotic lesion 
development and vulnerable plaque formation. Impaired ability of arterial 
phagocytes to uptake apoptotic cells (efferocytosis) promotes lesion 
growth and establishment of a necrotic core. The transcription factor 
interferon regulatory factor (IRF)-5 is an important modulator of myeloid 
function and programming. We sought to investigate whether IRF5 
affects the formation and phenotype of atherosclerotic lesions.
METHODS: We investigated the role of IRF5 in atherosclerosis in 2 
complementary models. First, atherosclerotic lesion development in 
hyperlipidemic apolipoprotein E-deficient (ApoE‒/‒) mice and ApoE‒/‒ mice 
with a genetic deletion of IRF5 (ApoE‒/‒Irf5‒/‒) was compared and then 
lesion development was assessed in a model of shear stress-modulated 
vulnerable plaque formation.
RESULTS: Both lesion and necrotic core size were significantly reduced in 
ApoE‒/‒Irf5‒/‒ mice compared with IRF5-competent ApoE‒/‒ mice. Necrotic 
core size was also reduced in the model of shear stress-modulated 
vulnerable plaque formation. A significant loss of CD11c+ macrophages 
was evident in ApoE‒/‒Irf5‒/‒ mice in the aorta, draining lymph nodes, 
and bone marrow cell cultures, indicating that IRF5 maintains CD11c+ 
macrophages in atherosclerosis. Moreover, we revealed that the CD11c 
gene is a direct target of IRF5 in macrophages. In the absence of IRF5, 
CD11c‒ macrophages displayed a significant increase in expression of 
the efferocytosis-regulating integrin-β3 and its ligand milk fat globule-
epidermal growth factor 8 protein and enhanced efferocytosis in vitro 
and in situ.
CONCLUSIONS: IRF5 is detrimental in atherosclerosis by promoting 
the maintenance of proinflammatory CD11c+ macrophages within 
lesions and controlling the expansion of the necrotic core by impairing 
efferocytosis.
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Atherosclerosis, through causing heart attacks and strokes, is responsible for nearly half of deaths worldwide.1 The presence of mononucle-
ar phagocytes within the innermost intimal layer of the 
arterial wall is the hallmark of atherosclerosis and is nec-
essary for its development.2,3 The variety of macrophage 
subsets described in atherosclerosis is testament to the 
plasticity of this cell, with cell programming driven by 
lipids, inflammation, and hemorrhage.4 Macrophages 
are crucial for programmed apoptotic cell removal or 
efferocytosis during atherogenesis and inflammation.5 
Impaired efferocytosis, resulting from either the persis-
tent expression of don’t eat me signals such as CD47 
on apoptotic cells6 or the cleavage of efferocytic recep-
tors,7 leads to larger necrotic cores that are a feature of 
high-risk lesions. The mechanisms linking macrophage 
programming with efferocytosis function are ill defined.
The transcription factor interferon regulatory fac-
tor (IRF)-5 is a master regulator of inflammatory mac-
rophage programming.8,9 Granulocyte macrophage 
colony-stimulating factor (GM-CSF) and interferon-γ 
treatment increases IRF5 expression.8,9 Toll like receptor 
activation of myeloid differentiation primary response 
gene 88 signaling leads to phosphorylation of IRF5 and 
its nuclear translocation.9 Genetic deletion of IRF5 pro-
tects from murine inflammatory arthritis and insulin re-
sistance in diet-induced obesity,10,11 while its inhibition 
with nanoparticles decreases myocardial infarct size.12
Despite the widespread prevalence of atherosclerosis 
in the population, acute complications arise in vulnerable 
patients with unfavorable plaque morphologies, such as 
thin-cap fibroatheroma (TCFA). TCFA is characterized by 
a large necrotic core surrounded by a thin protective fi-
brous cap containing fewer smooth muscle cells.13 We 
have previously shown that hemodynamic factors may 
be relevant to TCFA formation. Low shear stress (LSS) oc-
curs in the inner curvatures of vessels (eg, in the aortic 
arch and coronary arteries) and upstream of stenosis. 
In murine models, exposure to LSS leads to the devel-
opment of plaque morphologies that resemble human 
TCFA.14 We have also previously shown that IRF5 expres-
sion is enhanced in arterial regions exposed to LSS.15
In the present study, we evaluated the effect of 
IRF5 deficiency on the development of atherosclerosis 
in 2 complementary murine models. Loss of IRF5 ex-
pression reduced aortic lesion and necrotic core size 
in atherosclerosis-prone apolipoprotein E-deficient 
(ApoE‒/‒) mice. Furthermore, arterial segments exposed 
to LSS developed smaller necrotic cores and displayed a 
higher content of smooth muscle cells in IRF5-deficient 
ApoE‒/‒ mice. Loss of IRF5 significantly reduced CD11c 
expression and infiltration of CD11c+ macrophages in 
the aorta and draining lymph nodes while promoting 
the ability of macrophages to perform efferocytosis 
by integrin β-3 (Itgb3) and milk fat globule-epidermal 
growth factor 8 protein (Mfge8). Our data indicate that 
IRF5 is a key regulator of efferocytosis and necrotic core 
formation in atherosclerosis.
METHODS
Mice
ApoE‒/‒ mice on a C57BL/6 background were purchased from 
Charles River Laboratories and bred in-house. Irf5‒/‒ mice on 
a C57BL/6 background (from Professor Irina Udalova) were 
bred with ApoE‒/‒ mice to generate ApoE‒/‒Irf5‒/‒ mice and 
their littermates (referred to as ApoE‒/‒ mice thereafter). 
Experimental animals were negative for the Dock2 muta-
tion.16 Animals were housed under specific pathogen-free 
conditions and studied according to UK Home Office regula-
tions and institutional guidelines. Only male mice were used 
in this study.
Clinical Perspective
What Is New?
• Using murine models of atherosclerosis, we pro-
vide evidence for a pathogenic role for the tran-
scription factor interferon regulatory factor (IRF5) 
in atherosclerosis.
• Atherosclerosis-prone apolipoprotein E-deficient 
(ApoE‒/‒) mice deficient in IRF5 (ApoE‒/‒Irf5‒/‒) 
exhibit reduced atherosclerotic lesion and necrotic 
core formation compared with IRF5-competent 
ApoE‒/‒ mice.
• We reveal that development of the lesion necrotic 
core is controlled by IRF5 through impairment 
of macrophage efferocytosis (dead cell removal) 
through the molecules milk fat globule-epidermal 
growth factor 8 protein  and integrin β-3 .
• We further demonstrate that the CD11c gene is a 
direct target of IRF5 in macrophages and that IRF5 
is important in maintaining CD11c+ macrophages 
in atherosclerotic lesions.
What Are the Clinical Implications?
• Larger necrotic cores are associated with an unsta-
ble atherosclerotic plaque phenotype, which is 
more likely to rupture and manifest as acute clinical 
complications.
• IRF5 contributes to a vulnerable plaque phenotype 
by maintaining proinflammatory CD11c+ macro-
phages in the plaque and impairing efferocytosis, 
causing larger necrotic cores.
• Currently, no therapies are available that specifi-
cally target plaque inflammation and efferocytosis 
and modulate plaque stability.
• IRF5 is a potential therapeutic target because IRF5 
inhibition could reduce plaque inflammation and 
necrotic core size and therefore promote a stable 
plaque phenotype with lower risk of acute clinical 
complications.
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Murine Lesion Analysis and Staining
Aortic root and cast-induced carotid lesion sections were 
stained and quantified as described in the online-only Data 
Supplement Methods. In situ efferocytosis was assessed in 
cast-induced carotid lesion sections stained for apoptosis 
(TUNEL), DNA (7AAD), and CD68 as described in online-only 
Data Supplement Methods.
Analysis of Aortas and Para-Aortic Lymph 
Nodes (PALNs)
Aortas and PALNs were harvested from 20-week-old ApoE‒/‒ 
and ApoE‒/‒Irf5‒/‒ mice. Single-cell suspensions were stained 
with antibodies and analyzed by flow cytometry or RNA 
was extracted and gene expression was analyzed using 
reverse transcription polymerase chain reaction, performed 
using Taqman assays as described in the online-only Data 
Supplement Methods.
Bone Marrow Macrophage Culture and 
Functional Assays
Bone marrow macrophages were isolated from ApoE‒/‒ and 
ApoE‒/‒Irf5‒/‒ mice and cultured with GM-CSF as described 
in online-only Data Supplement Methods. Functional assays 
including apoptosis, foam cell, phagocytosis, and efferocyto-
sis assays (including siRNA knockdown of Itgb3 and Mfge8) 
were then performed as described in the online-only Data 
Supplement Methods
Chromatin Immunoprecipitation and 
Next-Generation Sequencing
The IRF5 chromatin immunoprecipitation sequencing analysis 
was performed as previously described (accession number: 
E-MTAB-2661)17 to determine the role of IRF5 as a regulator 
of CD11c expression.
Human Carotid Plaques
Human carotid plaques from the Carotid Plaque Imaging 
Project biobank were analyzed as described in the online-only 
Data Supplement Methods. Informed consent was given by 
each patient, and the study was approved by the local ethical 
committee.
Statistical Methods
Data were analyzed with GraphPad Prism (v6.0c) or the R 
WRS2 package. Normally distributed variables are expressed 
as mean±SEM, and non-normally distributed variables are 
expressed as median and interquartile range (IQR). For aor-
tic root lesion area and immunohistochemical staining in 
ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice, the significance of changes 
in the main effects (time, genotype, and their interaction) was 
assessed using a robust 2-way ANOVA. For each parameter 
of interest in these data, Bonferroni-corrected nonparametric 
(Mann-Whitney U) planned tests were performed to assess 
the effect of genotype at each time point. Data from cast-
induced carotid lesions were similarly analyzed using a mixed 
robust 2-way ANOVA to account for the paired observations 
of low and oscillatory stress. We used Bonferroni-corrected 
nonparametric (Mann-Whitney U) planned tests to assess the 
effect of (1) genotype within stress type (unpaired test), and 
(ii) stress type within genotype (paired test). The use of non-
parametric and robust ANOVA methods was motivated by 
observations of non-normality and unequal group variances. 
The significant findings from the planned tests are reported 
in the figures, and results of the ANOVA analyses are sum-
marized in Tables I‒V in the online-only Data Supplement. 
In the remainder of the article, data were analyzed with 
Student’s t test, Mann-Whitney U test, 1-way ANOVA, and 
Spearman’s or Pearson’s correlation coefficient as appropri-
ate. The Benjamini-Hochberg method was used to adjust the 
P values for multiple testing as necessary.
RESULTS
IRF5 Is Expressed in Atherosclerotic 
Lesions by Myeloid Cells
Expression of IRF5 was examined in aortic root lesions 
of ApoE‒/‒ mice 12, 20, and 27 weeks of age. Maximal 
IRF5 expression (6.3±2.5% of lesion area) was observed 
at 20 weeks of age (Figure IA in the online-only Data 
Supplement). Using confocal microscopy, IRF5 staining 
in the atherosclerotic lesion was observed in CD68- and 
CD11c-expressing cells. Nuclear translocation could 
also be observed (Figure IB and C in the online-only 
Data Supplement). Conversely, expression of α-smooth 
muscle actin in the intima of the lesion did not colocal-
ize with IRF5 staining (Figure ID in the online-only Data 
Supplement).
IRF5 Deficiency Reduces Atherosclerotic 
Lesion and Necrotic Core Size
ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice were fed a chow diet 
and euthanized at 15, 20, or 27 weeks of age. No dif-
ference in serum cholesterol levels was observed be-
tween ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice at any time point 
examined (Table VI in the online-only Data Supple-
ment). ApoE‒/‒Irf5‒/‒ mice were heavier than ApoE‒/‒ 
mice at 15 weeks of age, in keeping with published 
studies (Table VI in the online-only Data Supplement ).10 
Lesion size was assessed in ApoE‒/‒ and ApoE‒/‒
Irf5‒/‒ mice at the level of the aortic root after staining 
with Oil Red O. ApoE‒/‒Irf5‒/‒ mice had smaller lesions 
than ApoE‒/‒ mice at 15 weeks of age (ApoE‒/‒ versus 
ApoE‒/‒Irf5‒/‒: 7.2% [IQR, 5.99–7.91] versus 4.44% 
[IQR, 2.99–6.48]; P=0.084). Similarly, IRF5-deficient 
ApoE‒/‒ mice had smaller lesions at 20 weeks of age 
(11.9% [IQR, 11.2–16.3] versus 9.5% [IQR, 7.85–10.7]; 
P=0.032; Figure 1A). No difference was observed at 27 
weeks of age. The smaller lesion size was accompa-
nied by a reduction in necrotic core formation, evalu-
ated using hematoxylin and eosin staining according 
to established protocols.18 In contrast to ApoE‒/‒ mice, 
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lesional necrotic core size was ≈70% smaller in ApoE‒/‒
Irf5‒/‒ mice at 20 weeks of age (20.4% [IQR, 16.7–27.9] 
versus 6.14% [IQR, 5.63–10.3]; P=0.0023) and ≈73% 
smaller at 27 weeks of age (32.9% [IQR, 29.7–36.3] 
versus 9% [IQR, 7.5–13.1]; P=6.5x10‒5; Figure 1B).
Lesions in the aortic root were further characterized 
by immunohistochemistry. A small increase in CD68 
(Figure  2A) immunopositive area percentage was ob-
served in the ApoE‒/‒Irf5‒/‒ mice across all the time 
points (P=0.045; Table II in the online-only Data Supple-
ment). However, this difference did not achieve statisti-
cal significance in the planned tests conducted at the 
individual time points or when CD68 immunopositivity 
was expressed as absolute area.
CD11c+ myeloid cells contribute to lipid accumu-
lation and the initiation of atherosclerosis.19 Hence, 
CD11c expression was examined. CD11c expression 
was significantly attenuated in aortic root lesions of 
ApoE‒/‒Irf5‒/‒ compared with ApoE‒/‒ mice with a 57% 
decrease at 20 weeks of age (8.65% [IQR, 5.8–10] ver-
sus 3.7% [IQR, 2.3–4.1]; P=0.0092) and an 80% reduc-
tion at 27 weeks of age (10.2% [IQR, 5.8–12.8] versus 
2.1% [IQR, 1.5–2.2]; P=0.0028) (Figure 2B). Conversely, 
a trend towards an increase in lesional smooth muscle 
cell α-actin content was seen in ApoE‒/‒Irf5‒/‒ mice at 
27 weeks of age (P=0.052; Figure IIA in the online-only 
Data Supplement).
IRF5 Deletion in Hypercholesterolemic 
Mice Modulates Macrophage Markers in 
Atherosclerotic Lesions
Necrotic core development is strongly related to the be-
havior of myeloid cell populations in particular macro-
phages.20 IRF5 defines a proinflammatory macrophage 
phenotype.8 Both proinflammatory and alternatively 
activated macrophages have been identified in athero-
sclerotic lesions.21,22 Thus, we investigated whether IRF5 
deletion affected the expression of macrophage mark-
ers within atherosclerotic plaques. Lesions were stained 
for the proinflammatory macrophage marker inducible 
nitric oxide synthase (iNOS), the alternatively activated 
macrophage marker CD206 (mannose receptor), and 
the lipid/heme driven Mox/Mhem macrophage marker 
heme oxygenase-1. Heme oxygenase-1 expression was 
significantly upregulated in the aortic root lesions of 
15-week-old ApoE‒/‒Irf5‒/‒ compared with ApoE‒/‒ mice 
(P=0.002; Figure IIB in the online-only Data Supple-
ment), as was lesional CD206 expression at 27 weeks 
of age (P=0.030; Figure 2C). No difference in lesional 
iNOS protein expression was seen at the time points 
studied by immunohistochemistry (Figure IIC in the on-
line-only Data Supplement).
To investigate the modification of myeloid cell pro-
gramming in the lesions, gene expression levels of a 
bespoke panel of myeloid markers were quantified in 
the aortic arch of 20-week-old mice, the time point at 
which the maximum difference in lesion size between 
ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice was observed. The 
levels of gene expression of Itgax (CD11c; P=1x10‒6), 
Cd68 (P=0.0016), Nos2 (P=0.0016), and tumor necrosis 
factor-α (P=0.0017) were significantly reduced in the 
aorta of ApoE‒/‒Irf5‒/‒ compared with ApoE‒/‒ mice, 
whereas Irf4 (P=0.0023) and Il4 (P=5x10‒5), were up-
regulated (Figure 3A). A similar pattern of gene expres-
sion was found in the aorta at 27 weeks of age (Fig-
ure 3B) and the PALNs (situated by the iliac bifurcation, 
a common site of atherosclerotic plaque development; 
Figure 3C).
IRF5 Deficiency Reduces Shear Stress-
Modulated Plaque Vulnerability
A perivascular shear stress-altering cast, which is surgi-
cally tied around the carotid artery of ApoE‒/‒ mice, has 
been shown to mimic human shear stress patterns and 
generates atherosclerotic lesions with TCFA morpholo-
gy in mice. In this model, LSS induces macrophage-rich 
vulnerable plaques, and oscillatory shear stress (OSS) 
produces smooth muscle cell-rich stable plaques.14 We 
previously showed that IRF5 expression is enhanced at 
the LSS-exposed region of the carotid artery, in keeping 
with higher expression of inflammatory macrophage 
markers, including iNOS at this site.15
To investigate whether IRF5 modulates plaque size 
and composition in a murine model of TCFA, ApoE‒/‒, 
and ApoE‒/‒Irf5‒/‒ mice were fed a high-fat diet for 2 
weeks before undergoing surgery to place the perivas-
cular shear stress-modifying cast. Animals were eutha-
nized and casts removed after 9 weeks. ApoE‒/‒Irf5‒/‒ 
mice fed a high-fat diet were found to be significantly 
heavier than ApoE‒/‒ mice (Table VII in the online-only 
Data Supplement) as previously published.10 However, 
no differences in serum cholesterol levels were detected 
between the 2 groups (Table VII in the online-only Data 
Supplement)).
No statistically significant differences were shown in 
lesion size between the 2 genotypes after cast place-
ment (Figure III in the online-only Data Supplement). 
The size of the necrotic core in the lesions induced by 
LSS was significantly smaller in ApoE‒/‒Irf5‒/‒ compared 
with ApoE‒/‒ mice (27.9% [IQR, 23–35.1] versus 5.65% 
[IQR, 4.93–6.83]; P=0.00062; Figure 4A), whereas no 
difference in necrotic core size of lesions in the OSS re-
gion was observed between the 2 genotypes. No dif-
ferences were observed in the expression of CD68 (Fig-
ure 4B), iNOS, CD206, or heme oxygenase-1 (Table VIII 
in the online-only Data Supplement).
CD11c expression was almost abrogated in both LSS- 
and OSS-modulated regions of the ApoE‒/‒Irf5‒/‒ carotid 
compared with ApoE‒/‒ mice (LSS: 6.41% [IQR, 5.35–
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8.17] versus 0.07% [IQR, 0.045–0.097]; P=0.0036; 
OSS: 4.09% [IQR, 2.04–5.48] versus 0.06% [IQR, 
0.027–0.125]; P=0.0037; Figure 4C). It is important to 
note that IRF5 deficiency increased the smooth muscle 
cell content in the LSS region (P=0.029; Figure 4D).
IRF5 Deficiency Reduces CD11c 
Expression in the Aorta, Draining Lymph 
Nodes, and Bone Marrow Cultures
A reduction in CD11c expression observed by both 
immunohistochemistry and gene expression quanti-
fication emerged as the most striking change in my-
eloid markers induced by IRF5 deficiency in vivo. To as-
sess whether differences in gene expression reflected 
changes in specific cell populations, 8-color flow cy-
tometry was performed on aortas, PALNs, and in vitro 
GM-CSF-derived bone marrow-derived cell cultures 
from ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice. In line with the 
gene expression data, ApoE‒/‒Irf5‒/‒ mice showed a sig-
nificant decrease in CD11c-expressing F4/80+CD11b+ 
and F4/80+CD11b+MerTK+ macrophages in the aorta 
and PALNs (Figure 5A and 5B and Figures IV and V in 
the online-only Data Supplement) compared to ApoE‒/‒ 
mice. There was also a decrease in the comparatively 
small CD11b+ dendritic cell population (P<0.05; Figure 
VI in the online-only Data Supplement). However, there 
was no change in CD103+ dendritic cells in the aorta 
of ApoE‒/‒Irf5‒/‒ compared with ApoE‒/‒ mice (Figure 
VI in the online-only Data Supplement). Attenuation of 
CD11c+ macrophage frequencies in ApoE‒/‒Irf5‒/‒ com-
pared with ApoE‒/‒ mice was also confirmed in GM-
CSF-derived bone marrow cell cultures (P<0.05; Fig-
ure 5C).
Chromatin immunoprecipitation revealed specific 
binding of IRF5 to the promoter region of Itgax (Fig-
ure 6A). Notably, the binding of IRF5 to the CD11c gene 
loci was dependent on lipopolysaccharide (LPS) stimula-
tion, with recruitment of IRF5, as detected by peak calling 
with MACS2, occurring in stimulated macrophages but 
not in untreated cells. This finding is in keeping with the 
key role of IRF5 as a stimulus-dependent transcription fac-
tor in the macrophage immune response. Next we aimed 
to investigate whether IRF5 regulates the expression of 
CD11c in GM-CSF-matured macrophages. The levels of 
Itgax (CD11c) expression were significantly reduced in 
LPS-treated GM-CSF-cultured bone marrow-derived mac-
rophages deficient in IRF5 (P<0.05; Figure 6B).
Next we explored the coexpression of IRF5 and 
CD11c within human atherosclerotic plaques. The ex-
pression of IRF5 and CD11c was assessed histologically 
in human carotid plaques from the Carotid Plaque Imag-
Figure 1. IRF5 deficiency decreases lesion and necrotic core size in the aortic root of ApoE‒/‒ mice.  
Representative images of aortic root sections from ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice 15, 20, or 27 weeks of age stained with Oil 
Red O and hematoxylin for lesion area (A). Graphs show cross-sectional aortic root lesion area (x103 μm2 and %) (B) hematox-
ylin and eosin for necrotic core delineation. Graphs show aortic root lesional necrotic core area (defined as anuclear, afibrotic, 
and eosin-negative areas) (x103 μm2 and %). Dotted lines show necrotic core area. Each circle represents the mean area per 
individual mouse. Horizontal line denotes group median (n=9 to 10). Bars=100μm. ApoE indicates apolipoprotein E-deficient; 
and IRF, interferon regulatory factor. *P<0.05; **P<0.01; ***P<0.001.
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ing Project biobank. As shown in Figure VIIA in the on-
line-only Data Supplement, IRF5 and CD11c were found 
to be coexpressed, and their coexpression appeared to 
be more marked in regions of the plaque that were ad-
jacent to the necrotic core. Furthermore, the percentage 
of CD11c expression positively correlated with IRF5 ex-
pression (r=0.57, P<0.05; Figure VIIB in the online-only 
Data Supplement), suggesting that similar to murine 
atherosclerosis there may be a role for IRF5 in regulating 
CD11c expression in human atherosclerotic disease.
IRF5 Deficiency Affects the Function of 
Myeloid Cell Subsets
Our data demonstrate that IRF5 deficiency in mice with 
hypercholesterolemia reduces both the intralesional ne-
crotic area and CD11c+ myeloid cell content. Next, we 
explored the mechanistic relationship between these 2 
observations by investigating whether IRF5 deficiency 
affected the functional behavior of myeloid cells in mice 
with hypercholesterolemia.
Bone marrow-derived cells were cultured in the pres-
ence of GM-CSF before being magnetically sorted into 
CD11c+ and CD11c‒ populations. The cells were then 
left unstimulated or activated with LPS. We investigat-
ed whether Irf5 deficiency modifies the phagocytosis 
and foam cell formation capacity of myeloid cells. The 
GM-CSF-cultured CD11c+ or CD11c‒ bone marrow 
cells were incubated with fluorescently labeled acety-
lated  human  low-density  lipoprotein or fluorescent 
microspheres to assess their phagocytosis efficiency. 
IRF5 deficiency did not affect the ability of the bone 
Figure 2. IRF5 deficiency reduces CD11c expression in the aortic root.  
A, Representative photomicrographs of aortic root sections from 15-, 20-, and 27-week-old ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice 
stained with an antibody against CD68 (brown staining) and hematoxylin. Graphs show aortic root lesion area staining posi-
tive (x103 μm2 and %) for CD68. B, Representative photomicrographs of aortic root sections from 15-, 20-, and 27-week-old 
ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice stained with an antibody against CD11c (brown staining) and hematoxylin. Arrows highlight 
CD11c+ positive cells. Graphs show aortic root lesion area staining positive (x103 μm2 and %) for CD11c. C, Representative pho-
tomicrographs of aortic root sections from 15-, 20-, and 27-week-old ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice stained with an antibody 
against CD206 (brown staining) and hematoxylin. Graphs show aortic root lesion area staining positive (x103 μm2 and %) for 
CD206 (n=9 to 10). Bars=100μm. Each circle represents the mean positive area per individual mouse. Horizontal line denotes 
group median. ApoE indicates apolipoprotein E-deficient; and IRF, interferon regulatory factor. *P<0.05; **P<0.01; ***P<0.001.
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marrow-derived cells to take up fluorescently labeled 
acetylated human low-density lipoprotein and become 
foam cells, nor did it affect their ability to perform bead 
phagocytosis (Tables IX and X in the online-only Data 
Supplement).
The amount of cell apoptosis is an important fac-
tor in necrotic core formation.23 Apoptosis was induced 
with ultraviolet light, cells were stained with propidium 
iodide and Annexin V, and apoptosis levels were mea-
sured by flow cytometry. It is interesting to note that 
late apoptosis was decreased in ApoE‒/‒Irf5‒/‒ CD11c‒ 
cells after activation with LPS (P<0.0001; Figure 7A and 
Table XI in the online-only Data Supplement).
Finally, the ability to perform apoptotic cell removal 
(efferocytosis) was examined by incubating the bone 
marrow-derived cells with fluorescently labeled apop-
totic Jurkat cells as previously published.18 The efficiency 
of efferocytosis by GM-CSF differentiated ApoE‒/‒Irf5‒/‒ 
CD11c‒ cells was ≈30% higher than that of differenti-
ated ApoE‒/‒ CD11c‒ cells (P<0.0001; Figure 7B).
To investigate whether the effect of IRF5 deficiency 
on efferocytosis was also observable in situ, carotid 
plaque sections were costained for apoptosis with TU-
NEL stain and CD68 using previously described meth-
ods.24 In support of the in vitro data, the frequency of 
apoptotic cells was decreased in situ in ApoE‒/‒Irf5‒/‒ 
mice (P=0.04; Figure 7C). Conversely, the percentage of 
apoptotic cells undergoing efferocytosis was enhanced 
in plaque tissue obtained from IRF5-deficient ApoE‒/‒ 
mice (P=0.001; Figure 7C). 
In summary, IRF5 deficiency promotes the viability of 
CD11c‒ GM-CSF-derived bone marrow macrophages 
and their ability to perform efferocytosis, but it does 
not affect their ability to phagocytose lipid or beads.
IRF5 Suppresses Efferocytosis-Regulating 
Genes In Vitro and In Situ
To further explore how IRF5 may interfere with myeloid 
cell capacity to perform efferocytosis, gene expression 
of the most characterized receptors for efferocytosis, 
the TAM (Tyro3, Axl, and Mer) receptors tyrosine-pro-
tein kinase Mer (MerTK), Axl, and Tyro3, as well as Itgb3 
(which forms the αvβ3 receptor with alpha 5 integrin), 
were analyzed in GM-CSF-matured bone marrow-de-
rived myeloid cell cultures.
GM-CSF-matured cells from ApoE‒/‒Irf5‒/‒ mice dis-
played significantly higher gene expression of Itgb3 
compared with cells from ApoE‒/‒ mice (P=0.0037; Fig-
ure 8A). A small increase in Tyro3 expression was also 
found (P=0.013; Figure 8A), whereas no effect on the 
gene expression of MerTK or Axl was observed. Since 
in vitro-matured cells may not always reflect the pheno-
type of cells matured in vivo, we next assessed the ex-
Figure 3. Decreased gene expression of inflammatory and myeloid cell markers in ApoE–/–Irf5–/– mice.  
The aortic arches and PALNs of ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice were collected and RNA extracted. Gene expression of inflam-
matory and myeloid cell markers was then assessed by reverse transcription polymerase chain reaction. A and B, Graphs show 
gene expression of selected genes in the aortic arch of ApoE‒/‒ (black bars) and ApoE‒/‒Irf5‒/‒ mice (white bars) at 20 (A) and 
27 (B) weeks of age. C, Graph shows gene expression of selected genes in the PALN of ApoE‒/‒ (black bars) and ApoE‒/‒Irf5‒/‒ 
mice (white bars) at 20 weeks of age. Data are presented as fold change (n=8). Bars=mean+SEM. ApoE indicates apolipopro-
tein E-deficient; IRF, interferon regulatory factor; and PALN, para-aortic lymph nodes. **P<0.01; ***P<0.001.
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pression of efferocytosis-regulating genes in the aortas 
of ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice. Again, Itgb3 ex-
pression was significantly higher in the aortas of ApoE‒/‒ 
Irf5‒/‒ compared with ApoE‒/‒ mice (P=0.0006; Fig-
ure 8B). The increase in Itgb3 gene expression in IRF5-
deficient ApoE‒/‒ mice was also confirmed at the level 
of cell surface protein expression using flow cytometry 
(P<0.05; Figure 8C). It is important to note that the in-
crease in Itgb3 was restricted to CD11c‒ macrophages, 
in keeping with the results of the functional efferocy-
tosis assays.
We next assessed gene expression of the ligand of 
αvβ3, Mfge8, and the ligands for the TAM receptors: 
growth arrest-specific 6 and protein S in GM-CSF-
derived bone marrow myeloid cells. The gene expres-
sion of Mfge8 was found to be significantly higher in 
ApoE‒/‒Irf5‒/‒ compared with ApoE‒/‒ mice (P=0.0085; 
Figure 8A). This increase in Mfge8 gene expression was 
also present in the aorta of ApoE‒/‒Irf5‒/‒ compared 
with ApoE‒/‒ mice (P=0.01; Figure 8B). No differences 
in gene expression of the TAM receptors ligands growth 
arrest-specific 6 or protein S were found between 
ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice in vitro or in situ (Fig-
ure 8A and 8B).
Since Mfge8 acts as a ligand between αvβ3 and 
phosphatidylserine on apoptotic cells, the secretion of 
the protein is crucial for its effects in the lesion. Here-
in, Mfge8 levels were analyzed in supernatants of the 
Figure 4. IRF5 deficiency decreases necrotic core formation and CD11c expression in shear stress-modulated lesions. 
ApoE‒/‒ (black circles) and ApoE‒/‒Irf5‒/‒ mice (white circles) were placed on a high-fat diet at 17 to 18 weeks of age. After 2 
weeks, a perivascular shear stress-altering cast was surgically placed around the common carotid artery and left in place for 
9 weeks. A, Representative photomicrographs of carotid artery sections stained with hematoxylin and eosin. Graphs show 
lesional necrotic core area (defined as anuclear, afibrotic, and eosin-negative areas) (x1000 μm2 and %). Solid lines show 
necrotic core area. B, Representative photomicrographs of carotid sections stained with an antibody against CD68 (brown 
staining) and hematoxylin. Graphs show lesion area staining positive (x1000 μm2 and %) for CD68. Dotted lines denote lesion 
area. C, Representative photomicrographs of carotid sections stained with an antibody against CD11c (brown staining) and 
hematoxylin. Graphs show lesion area staining positive (x1000 μm2 and %) for CD11c. Dotted lines denote lesion area. D, 
Representative photomicrographs of carotid sections with an antibody against smooth muscle cell ɑ-actin (ASMA) (Cy3-red). 
Graphs show aortic root lesion area staining positive (x1000 μm2 and %) for ASMA. Dotted lines denote lumen. Bars=100μm 
in A through C and 80 μm in D (n=8). Each circle represents the mean positive area per individual mouse. Horizontal line 
denotes group median. ApoE indicates apolipoprotein E-deficient; IRF, interferon regulatory factor; and SMC, smooth muscle 
cell. *P<0.05; **P<0.01; ***P<0.001.
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in vitro bone marrow cell cultures. Mfge8 levels were 
found to be significantly higher in the supernatants 
from ApoE‒/‒Irf5‒/‒ compared with ApoE‒/‒-derived cells 
cultured in GM-CSF (P=0.005; Figure 8D).
To investigate whether the enhanced capacity to 
perform efferocytosis in Irf5-deficient macrophages 
was Itgb3 or Mfge8 dependent, additional knockdown 
experiments were performed. Using siRNA, Mfge8 and 
Itgb3 were knocked down in GM-CSF-derived bone 
marrow-derived macrophages from Irf5-deficient and 
Irf5-competent ApoE‒/‒ mice. The increase in Itgb3 and 
Mfge8 gene expression in Irf5-deficient compared with 
Irf5-competent ApoE‒/‒ mice was confirmed in the con-
trol siRNA conditions (P<0.05 and P<0.01, respectively; 
Figure 8E). Next, the effect of siRNA knockdown was 
assessed using quantitative reverse transcription poly-
merase chain reaction. The gene expression of both 
Itgb3 and Mfge8 were confirmed to be significantly 
suppressed in IRF5-deficient macrophages after siRNA 
transfection (P<0.05 and P<0.001, respectively; Fig-
ure 8E). Using flow cytometry, knockdown of Itgb3 was 
confirmed in IRF5-deficient macrophages at the protein 
level (Figure 8F).
To assess whether the knockdown of Itgb3 or Mfge8 
affected the efferocytosis capacity of Irf5-deficient mac-
rophages, the in vitro efferocytosis assay was repeated. 
A significantly increased efferocytosis capacity in the 
uptake of apoptotic Jurkat cells in the Irf5-deficient 
group compared with the Irf5-competent group was 
confirmed in the siRNA control groups (37.7% ± 5.4% 
versus 60.3% ± 8.3%, P<0.05; Figure 8G). Knockdown 
of either Itgb3 or Mfge8 decreased the efferocytic abil-
ity and thus reversed the in vitro phenotype of the 
IRF5-deficient macrophages to the level of those from 
IRF5-competent mice (60.3% ± 8.3% versus 28.8% 
± 6.4%, P<0.01 and 60.3% ± 8.3% versus 27.6% ± 
2.6%, P<0.01; Figure 8G).
DISCUSSION
Myeloid cells are powerful contributors to the devel-
opment and complications of atherosclerosis. IRF5 is a 
master regulator of myeloid cell function and program-
ming in mouse and human.8 We show that IRF5 dele-
tion in ApoE‒/‒ mice reduces aortic atherosclerotic lesion 
size and also decreases the expression of the integrin 
CD11c in both macrophages and atherosclerotic le-
sions. In sharp contrast, IRF5 deficiency enhances both 
the expression of the integrin Itgb3 and its bridging li-
gand Mfge8 and the ability of myeloid cells to perform 
efferocytosis. This finding leads to a significant decrease 
in the necrotic core size in aortic atherosclerosis and 
LSS-induced TCFA lesions, demonstrating that IRF5 is 
instrumental in necrotic core formation.
IRF5 Affects the Lesional Content of 
CD11c+ Macrophages
CD11c+ myeloid cells are present in the arterial wall 
at athero-susceptible sites exposed to alterations in 
hemodynamic stress, such as curvatures and bifurca-
tions.25 CD11c expression by monocytes is upregu-
lated by hypercholesterolemia,26 and depletion of 
CD11c+ cells has been shown to reduce atherogenesis 
in ApoE‒/‒ mice.19,26 Collectively, these studies indicate 
Figure 5. IRF5 affects myeloid cell phenotype in the 
aorta, para-aortic lymph nodes, and in vitro bone mar-
row cultures.  
Aortas, PALNs, and bones were harvested from 20- to 
24-week-old ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice. Single-cell 
suspensions were then stained with antibodies against my-
eloid cell markers and analyzed by flow cytometry. Dead cells 
and debris were excluded from the analysis, and cells were 
gated on CD45+ cells. A, Graphs show the numbers of aortic 
CD11c+ macrophages (gated as CD45+CD11b+F4/80+cells 
or as CD45+CD11b+F4/80+MerTK+), expressed as a percent-
age of CD45+ cells (n=8). B, Graphs show the numbers of 
CD11c+ macrophages in the PALNs, expressed as a percent-
age of CD45+ cells (n=8). C, Graphs show the numbers of 
CD11c+- and CD11c- expressing macrophages in GM-CSF-
derived macrophage cultures in vitro, expressed as a percent-
age of CD45+ cells (n=4). Each circle represents an individual 
mouse. Horizontal line denotes group mean. ApoE indicates 
apolipoprotein E-deficient; IRF, interferon regulatory factor; 
MerTK, tyrosine-protein kinase Mer; and PALN, para-aortic 
lymph nodes. *P<0.05.
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the existence of proatherogenic CD11c+ myeloid cell 
populations.
In the present study, we observed a significant reduc-
tion in lesional CD11c staining in the absence of IRF5 
in both hypercholesterolemia-induced and LSS-induced 
murine atherosclerosis models. Using flow cytometry 
to pinpoint the specific cell subsets affected by IRF5 de-
ficiency, we were able to show a reduction in CD11c+ 
macrophages in the aortic lesions and draining lymph 
nodes. The reduction in CD11c expression was con-
firmed at the gene level in aortas and PALNs from IRF5-
deficient ApoE‒/‒ mice. Loss of CD11c was also evident 
in vitro in IRF5-deficient GM-CSF-matured macrophages. 
In a chromatin immunoprecipitation sequencing survey 
of genome-wide IRF5 binding sites in GM-CSF cultured 
bone marrow-derived macrophages, a specific binding 
site was revealed in the promoter region of the Itgax 
(CD11c) gene. In addition, the level of CD11c gene ex-
pression was significantly reduced in macrophages de-
rived from IRF5-deficient ApoE‒/‒ mice upon LPS stimula-
tion. These data suggest that on activation IRF5 directly 
regulates the gene expression of CD11c in macrophages.
We have previously shown that IRF5 promotes an 
inflammatory macrophage phenotype by direct regula-
tion of selected cytokines and surface receptors,8,10,11,17 
and it is now widely used as a marker of inflammatory 
macrophages.27,28 This study adds Itgax (CD11c) to the 
list of IRF5-regulated markers that define an inflamma-
tory macrophage phenotype. The involvement of the in-
tegrin CD11c in cell adhesion,29 monocyte/macrophage 
recruitment,26 and modulation of IL-1 production30 is 
well documented in the context of atherosclerosis.
Figure 6. IRF5 regulates CD11c expression.  
A, Chromatin immunoprecipitation and next-generation sequencing (ChIP-seq) of IRF5 binding sites from unstimulated and 
LPS-stimulated GM-CSF bone marrow-derived cells revealed specific binding of the transcription factor to the promoter region 
of ITGAX in GM-CSF-cultured bone marrow-derived macrophages. Notably, the binding of IRF5 to the ITGAX gene loci is de-
pendent on LPS stimulation, with recruitment of IRF5, as detected by peak calling with MACS2, occurring in stimulated mac-
rophages but not in untreated cells. B, Graph shows the fold change of CD11c gene expression in unstimulated or LPS-stimu-
lated GM-CSF bone marrow-derived cells from ApoE‒/‒ (black bars) or ApoE‒/‒Irf5‒/‒ (white bars) mice. CD11c gene expression 
is downregulated in GM-CSF-matured bone marrow-derived macrophages from IRF5-deficient mice upon LPS stimulation 
(n=6 to 10). Data are presented as mean±SEM. ApoE indicates apolipoprotein E-deficient; GM-CSF, granulocyte-macrophage 
colony-stimulating factor; IRF, interferon regulatory factor; Itgb3, integrin-β3; and LPS, lipopolysaccharide. *P<0.05.
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The expression of CD11c has previously been shown 
to associate with proinflammatory macrophage pheno-
type in obesity.31 Loss of aortic CD11c gene expression 
in IRF5-deficient mice was associated with a reduction 
in the aortic expression of proinflammatory genes such 
as iNOS and tumor necrosis factor-α, and an increase 
in genes associated with alternatively activated macro-
phages such as interleukin 4 and IRF4, indicating that 
IRF5 is responsible for a shift toward a proinflamma-
tory myeloid cell programming in atherosclerosis. IRF5 
induced other changes in macrophage phenotype in 
a time-dependent manner. At early stages of disease, 
heme oxygenase-1 expression was increased in lesions 
of ApoE‒/‒Irf5‒/‒ compared with ApoE‒/‒ mice, whereas 
at more advanced stages, CD206 expression was in-
creased in ApoE‒/‒Irf5‒/‒ lesions. The change in CD206 
expression fits with the observed increase in gene ex-
pression of M2-inducing interleukin 4 and IRF4 in the 
aorta. Our data indicate that CD11c expression is the 
hallmark of an IRF5-dependent subset of macrophages 
with a detrimental role in atherosclerosis.
GM-CSF is a strong inducer of IRF5 expression.8 Our 
data show that IRF5 deletion decreases the representa-
tion of CD11c+ bone marrow-derived myeloid cells af-
ter differentiation with GM-CSF. This observation is in 
keeping with previous studies reporting that GM-CSF 
has an important role in the maintenance of CD11c+ 
myeloid cells in atherosclerosis.32
In support of our findings in murine atherosclerosis, 
a significant association between IRF5 and CD11c ex-
pression was also found in human atherosclerotic tissue 
(Figure VIIA in the online-only Data Supplement). IRF5 
gene expression has previously been shown to be in-
creased in human atherosclerotic tissue compared with 
control tissue, but less is known about the potential 
effects of IRF5 activity in human plaque biology.33 The 
present findings support a role for IRF5 as an important 
transcription factor, potentially supporting an inflam-
matory macrophage subset identifiable by the expres-
sion of CD11c in human disease. 
Collectively, our data indicate that IRF5 is an impor-
tant factor for the maintenance of CD11c+ myeloid 
cell populations within atherosclerotic lesions and also 
directly regulates the expression of CD11c on macro-
phages.
IRF5 Increases Necrotic Core Size by 
Impairing Myeloid Cell Efferocytosis
The association between IRF5 and efferocytosis has 
not been previously described. In the present study, we 
show that IRF5 deficiency is associated with decreased 
necrotic core size, in both a standard hypercholesterol-
emia-driven model and a shear stress-modulating sur-
gical model known to form TCFA.15 The necrotic core 
in atherosclerotic plaques arises because of a combina-
tion of macrophage apoptosis and defective efferocy-
tosis (uptake of apoptotic cells).5 The capacity of mac-
rophages to perform efferocytosis and phagocytosis is 
thought to be broadly dependent on their activation 
and polarization status, with efferocytosis being inhib-
ited by tumor necrosis factor-α34,35 and enhanced by 
interleukin 4/ interleukin 13 and peroxisome prolifera-
tor-activated receptor-γ signaling.21,36 The dysregulated 
Figure 7. IRF5 deficiency reduces cellular apoptosis and increases efferocytosis. 
Bone marrow cells from ApoE‒/‒ (black bars) and ApoE‒/‒Irf5‒/‒ (white bars) mice 16 to 20 weeks of age were cultured in GM-
CSF for 7 days, and their ability to undergo apoptosis and to perform efferocytosis was assessed. A, Graph shows percentage of 
CD11c+ and CD11c‒ cells staining positive for propidium iodide and Annexin V after LPS stimulation and ultraviolet light exposure 
(n=8). B, Graph shows percentage of apoptotic Jurkat cell uptake by CD11c+ and CD11c- macrophages (n=8). C, Representative 
images of perivascular flow-modifying cast-induced carotid lesions in ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice stained with an antibody 
against CD68 (red) and TUNEL stained (green) and DNA (blue). Graphs show number of apoptotic cells (left) and percentage (right) 
of apoptotic cells undergoing efferocytosis in situ (n=4 to 5). Data are presented as mean±SEM. Black bars, ApoE‒/‒.. White bars, 
ApoE‒/‒Irf5‒/‒. ApoE indicates apolipoprotein E-deficient; and IRF, interferon regulatory factor. *P<0.05; **P<0.01; ***P<0.001.
Interferon Regulatory Factor 5 Impairs Efferocytosis
Circulation. 2017;136:1140–1154. DOI: 10.1161/CIRCULATIONAHA.117.027844 September 19, 2017 1151
ORIGINAL RESEARCH 
ARTICLE
inflammation present in advanced lesions is thought 
to play a role in disabling efferocytosis.20 However, the 
specific transcriptional regulators impairing efferocyto-
sis in atherosclerosis are poorly defined.
IRF5 deletion uncovered a complex interaction be-
tween CD11c expression and myeloid cell capacity to 
perform efferocytosis. Isolated CD11c‒ cells from GM-
CSF-derived bone marrow cultures from IRF5-deficient 
ApoE‒/‒ mice performed efferocytosis to a significantly 
greater extent than CD11c‒ cells from IRF5-competent 
ApoE‒/‒ mice. Furthermore, IRF5 deletion selectively af-
fected macrophage efferocytosis and did not interfere 
with phagocytosis or lipid uptake functions, suggesting 
that IRF5 plays a selective role in efferocytosis. Our data 
support the concept that macrophage programming 
consists of modules that can be activated independent-
ly of others rather than an en bloc phenotype.
The mechanism of efferocytosis is dependent on spe-
cific receptors and bridging molecules and is distinct 
from phagocytosis. Efferocytosis prevents secondary 
necrosis and is crucial for regulating and resolving the 
inflammatory response in atherosclerotic lesions.20 Be-
cause IRF5 clearly affected the ability of CD11c‒ cells to 
perform efferocytosis, we sought to identify potential 
Figure 8. IRF5 deficiency increases efferocytosis by CD11c‒ cells by an upregulation of Itgb3 and Mfge8.  
A, Gene expression (shown as fold change) of efferocytosis regulating receptors (Itgb3, MerTK, Axl, and Tyro3) and effe-
rocytosis-regulating bridging molecules (Mfge8, Gas6, and Protein S) in GM-CSF-matured macrophage cell cultures from 
ApoE‒/‒ (black bars) and ApoE‒/‒Irf5‒/‒ (white bars) mice 16 to 20 weeks of age (n=6 to 8). Data presented as median and IQR. 
B, Gene expression (shown as fold change) of efferocytosis-regulating receptors (Itgb3, MerTK, Tyro3, CD36, and CD14) and 
receptor ligands (Mfge8, Gas6, and Protein S) in the aorta of 20-week-old ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice (n=5 to 8). Data 
presented as median and IQR. C, CD11c‒ GM-CSF-matured macrophages from ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice were stained 
with an antibody against Itgb3. Representative plots show Itgb3 expression on CD11c- cells and graphs show numbers (left) of 
CD11c‒ cells expressing Itgb3 and the median fluorescent intensity (MFI) of Itgb3 staining (right) (n=6). Horizontal bars denote 
group median. D, Bone marrow-derived cells from ApoE‒/‒ and ApoE‒/‒Irf5‒/‒ mice were cultured in GM-CSF for 7 days, and 
Mfge8 released into the supernatant was assessed by ELISA (n=8). Data are presented as median and IQR. E, Gene expression 
level (fold change) of Itgb3 (left) and Mfge8 (right) in GM-CSF-matured macrophages from ApoE‒/‒ (black bars) and ApoE‒/‒
Irf5‒/‒ (white bars) mice after transfection with siRNA against Itgb3, Mfge8, or a control siRNA. Graphs show mean and SEM 
(n=3). F, Histogram overlay of Itgb3 protein expression, as assessed by flow cytometry, on GM-CSF-matured macrophages 
after transfection with siRNA against Itgb3 (red) or control (blue). G, Percentage of apoptotic Jurkat cell uptake by GM-CSF-
cultured macrophages from ApoE‒/‒ (black bars) and ApoE‒/‒Irf5‒/‒ (white bars) mice after transfection with siRNA against 
Itgb3, Mfge8, or a control siRNA. Graphs show mean and SEM (n=4). ApoE indicates apolipoprotein E-deficient; Ctrl, con-
trol; GM-CSF, granulocyte-macrophage colony-stimulating factor; IRF, interferon regulatory factor; Itgb3, integrin-β3; MerTK, 
tyrosine-protein kinase Mer; and Mfge8, milk fat globule-epidermal growth factor 8 protein. *P<0.05; **P<0.01; ***P<0.001.
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efferocytosis pathways that Irf5 may regulate. MerTK 
is a member of the TAM receptor tyrosine kinases that 
have important functions in efferocytosis and regulation 
of innate immunity.37 Defective efferocytosis induced by 
the deletion of MerTK accelerates atherosclerosis and 
necrotic core formation.24 However, in our study, MerTK+ 
macrophages were decreased in lesions in ApoE‒/‒Irf5‒/‒ 
mice. This finding is in keeping with a recent article by 
Cai et al,7 which highlighted that proteolytic cleavage of 
MerTK occurs in atherosclerosis and supports necrotic 
core formation. The lack of enhancement of MerTK 
protein expression in IRF5-deficient mice suggested that 
other efferocytosis pathways were at play.
The αvβ3 integrin is known to be a powerful media-
tor of efferocytosis through binding to phosphatidylser-
ine on apoptotic cells by the bridging molecule Mfge8. 
Itgb3 is one of the regulating parts of the αvβ3 integrin.
38 
Mfge8 is a glycoprotein secreted by macrophages that 
binds strongly to cells expressing αvβ3 integrin. Deplet-
ing Mfge8 inhibits efferocytosis, and Mfge8 deficiency 
in atherosclerosis models accelerates atherosclerosis and 
leads to the accumulation of apoptotic cells.38,39 Howev-
er, the role of Itgb3 on atherosclerotic efferocytosis has 
been less well described, and a role for IRF5 in regulat-
ing Itgb3 has not previously been shown. Both Itgb3 and 
its ligand Mfge8 were significantly upregulated in both 
the aorta and GM-CSF-derived cells from IRF5-deficient 
ApoE‒/‒ mice. Moreover, when Itgb3 and Mfeg8 were 
knocked down, the efferocytic phenotype of the IRF5-
deficient cells was reversed, suggesting that the Mfeg8‒
Itgb3 pathway was responsible for the increased ability 
of IRF5-deficient macrophages to perform efferocytosis. 
In summary, we provide evidence for an important role 
of Irf5 in impairing efferocytosis through the reduction 
of expression of Itgb3 and Mfge8.
Deletion of IRF5 might affect intralesional macro-
phage content through mechanisms other than effero-
cytosis. Macrophages from IRF5-deficient ApoE‒/‒ mice 
were resistant to apoptosis in vitro, and this observation 
is supported by intralesional TUNEL staining. In keep-
ing with this observation, we observed a small increase 
in the CD68 immunopositive area percentage across all 
time points. Thus, the effect of IRF5 deletion on lesional 
CD68+ cell content could possibly be explained by the 
complex role of IRF5 in cell survival and efferocytosis.
Our data reveal that IRF5 deletion has a significant 
effect on macrophage phenotype and function in ath-
erosclerosis. IRF5 is expressed by monocytes, macro-
phages, conventional dendritic cells, plasmacytoid den-
dritic cells, B cells, and some stromal cells.40 Although 
the expression of IRF5 within mouse and human ath-
erosclerotic lesions appeared to be confined to myeloid 
cells, our data (obtained with a global genetic deletion 
of IRF5) cannot exclude indirect effects arising from the 
deletion of IRF5 in other cell types and thus is a limita-
tion of our study.
CONCLUSIONS
In summary, the transcription factor Irf5 has a detri-
mental effect in atherosclerosis by affecting plaque 
formation and stability through the modulation of 
macrophage phenotype and function. IRF5 activation 
directly regulates expression of the integrin CD11c on 
macrophages and promotes the maintenance of pro-
inflammatory CD11c+ macrophages within the lesions. 
Moreover, IRF5 actively contributes to the impairment of 
efferocytosis, and its deletion ameliorates the formation 
of the necrotic core by the upregulation of the integrin 
Itgb3 and its ligand Mfge8 (Figure VIII in the online-only 
Data Supplement). Our study highlights the existence of 
equilibrium between CD11c+ and CD11c‒ Itgb3+ mac-
rophage subsets within atherosclerotic lesions, which 
significantly impacts the formation of the necrotic core.
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